- Home
- ABVC vs CLDI Comparison
ABVC vs CLDI Comparison
Compare ABVC & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- CLDI
- Stock Information
- Founded
- ABVC 2015
- CLDI 2014
- Country
- ABVC United States
- CLDI United States
- Employees
- ABVC N/A
- CLDI N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABVC Health Care
- CLDI Health Care
- Exchange
- ABVC Nasdaq
- CLDI Nasdaq
- Market Cap
- ABVC 16.7M
- CLDI 15.7M
- IPO Year
- ABVC N/A
- CLDI N/A
- Fundamental
- Price
- ABVC $1.33
- CLDI $0.44
- Analyst Decision
- ABVC
- CLDI Strong Buy
- Analyst Count
- ABVC 0
- CLDI 2
- Target Price
- ABVC N/A
- CLDI $15.00
- AVG Volume (30 Days)
- ABVC 213.2K
- CLDI 202.2K
- Earning Date
- ABVC 04-30-2025
- CLDI 05-13-2025
- Dividend Yield
- ABVC N/A
- CLDI N/A
- EPS Growth
- ABVC N/A
- CLDI N/A
- EPS
- ABVC N/A
- CLDI N/A
- Revenue
- ABVC $508,383.00
- CLDI N/A
- Revenue This Year
- ABVC $735.18
- CLDI N/A
- Revenue Next Year
- ABVC N/A
- CLDI N/A
- P/E Ratio
- ABVC N/A
- CLDI N/A
- Revenue Growth
- ABVC 1904.43
- CLDI N/A
- 52 Week Low
- ABVC $0.40
- CLDI $0.35
- 52 Week High
- ABVC $1.40
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- ABVC 71.45
- CLDI 33.95
- Support Level
- ABVC $1.01
- CLDI $0.41
- Resistance Level
- ABVC $1.00
- CLDI $0.46
- Average True Range (ATR)
- ABVC 0.09
- CLDI 0.04
- MACD
- ABVC 0.03
- CLDI 0.01
- Stochastic Oscillator
- ABVC 92.78
- CLDI 13.25
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.